Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Danish Study of Non-Invasive Diagnostic Testing in Coronary Artery Disease 3 (Dan-NICAD 3)

26 de enero de 2021 actualizado por: University of Aarhus

In a cohort of symptomatic patients referred to coronary computed tomography angiography (CCTA), the investigators aim is:

  1. To investigate and compare the diagnostic precision of Rubidium Positron Emission Tomography (Rb PET) and 15O-water PET (15O-water PET) in patients where CCTA does not exclude obstructive coronary artery disease (CAD) using invasive coronary angiography with fractional flow reserve (ICA-FFR) as reference standard.
  2. To study the diagnostic accuracy and prognostic value of computed tomography fractional flow reserve (CT-FFR) in patients where CCTA does not exclude obstructive CAD with ICA-FFR as reference standard.
  3. To validated a pre-test probability model including genetic and circulating biomarkers.
  4. To identify and characterize genetic risk variants and circulating biomarkers importance in developing CAD.
  5. To evaluate the bone mineral density in the hip and spine and correlate this to the degree of vascular calcification.

Descripción general del estudio

Descripción detallada

CCTA has become the preferred diagnostic modality for symptomatic patients with low to intermediate risk of CAD. Of the patients examined, CCTA exclude cardiovascular disease in 70-80% with an excellent negative predictive value of more than 95%. Having a low positive predictive value, however, CCTA often overestimates the severity of CAD, especially in patients with moderate to severe coronary calcification. Following CCTA, patients are hence unnecessarily tested using golden standard ICA-FFR. These ICAs often show no obstructive coronary stenosis and are therefore not followed by revascularization. The issues outlined raises the question of whether it is possible (1) to make a more precise risk stratification and consequently better selection of patients prior to CCTA and (2) to reduce the number of patients referred for unnecessary ICAs following CCTA.

In patients with suspicion of coronary stenosis detected by CCTA, current guidelines recommend verification of myocardial ischemia. Dan-NICAD 3 investigate the diagnostic accuracy of advanced non-invasive myocardial perfusion imaging tests; Rb PET and 15O-water PET. These examinations have shown a high diagnostic accuracy in symptomatic patients with high risk of ischemic heart disease. However, the diagnostic accuracy is not investigated in patients as follow-up after CCTA. In addition, microcirculation may impact the correlation between PET and ICA-FFR which this study will investigate further.

An alternative way to increase the diagnostic accuracy of CCTA and thus avoid unnecessary downstream testing using ICA is to utilize the ability to extract physiological information from the anatomical CCTA images. CT-FFR has in previous studies shown promising results. In addition, calculated estimation of microcirculatiory function is under development and this study will validated these algorithms. Furthermore, the prognostic value of CT-FFR is unknown and will be tested in the pooled cohort of Dan-NICAD 1, 2 and 3.

Obtained during ICA, quantitative flow ratio (QFR) is a novel wire-free approach for fast computation of FFR with potential to increase the global use of physiological lesion assessment. QFR is superior to traditional assessment of intermediate coronary lesions based on quantitative coronary analysis of ICA. However, disagreement between ICA-FFR and QFR has been identified in up to 20% of all measurements. QFR will be validated compared to PET and ICA-FFR.

Tipo de estudio

De observación

Inscripción (Anticipado)

1000

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

      • Herning, Dinamarca, 7400
        • Reclutamiento
        • Gødstrup Hospital
        • Contacto:

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

30 años a 100 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Método de muestreo

Muestra no probabilística

Población de estudio

Patients with an indication for CCTA.

Descripción

- Inclusion Criteria:

Patients with an indication for CCTA. Qualified patients who have signed a written informed consent form.

- Exclusion Criteria:

Demography and co-existing cardiac morbidity specific: Age below 30 years, patients having a donor heart, a mechanic heart, or mechanical heart pump, suspicion acute coronary syndrome or previous revascularization.

CCTA: Pregnant women, including women who are potentially pregnant or lactating, reduced kidney function, with an estimated glomerular filtration rate (eGFR) < 40 mL/min or allergy to X-ray contrast medium.

PET: contra-indication for adenosine (severe asthma, advanced atrioventricular block, or critical aorta stenosis).

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

Cohortes e Intervenciones

Grupo / Cohorte
Intervención / Tratamiento
Cohort

Participants consenting to the study will undergo:

a1) An interview a2) Blood samples withdrawals a3) ECG a4) Non-enhanced CT a5) CCTA a6) Follow-up for > 10 years

Patients with suspicion of coronary stenosis detected by CCTA will after undergo:

b1) Rb PET b2) 15O-water PET b3) Invasive coronary angiography with 3 vessel measurement of fractional flow reserve (FFR), coronary flow reserve (CFR) and index of microvascular resistance (IMR)

Head to head comparison with invasive FFR as reference. Adjustment for abnormal microcirculation

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Diagnostic accuracy of Rb PET and 15-O PET
Periodo de tiempo: ICA: 4 weeks after inclusion
Head-to-head comparison using ICA-FFR as reference standard stratified for CFR
ICA: 4 weeks after inclusion

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Diagnostic accuracy of QFR vs. ICA-FFR
Periodo de tiempo: ICA: 4 weeks after inclusion
Head-to-head comparison using ICA-FFR as reference standard
ICA: 4 weeks after inclusion
Pre-test probability model of CAD
Periodo de tiempo: ICA: 4 weeks after inclusion
Advanced pre-test probability model of CAD included clinical information, genetic and circulating biomarkers
ICA: 4 weeks after inclusion
Diagnostic accuracy of QFR
Periodo de tiempo: ICA: 4 weeks after inclusion
Head-to-head comparison using ICA-FFR as reference standard
ICA: 4 weeks after inclusion
Diagnostic accuracy of CT-FFR
Periodo de tiempo: ICA: 4 weeks after inclusion
Head-to-head comparison with PET using ICA-FFR as reference standard
ICA: 4 weeks after inclusion
Effect of reduced myocardial perfusion defect on symptoms of angina pectoris
Periodo de tiempo: Re-PET: 12 months after inclusion
12 months re-PET investigation will by used for estimation of reduction of myocardial perfusion defect size which will be correlated with symptoms of angina pectoris 3 and 12 mdr. after ICA
Re-PET: 12 months after inclusion
Prognostic value of clinical, biomarker, genetic information
Periodo de tiempo: Follow-up: Myocardial infarction and mortality rates after 3+5+10 years
Prognotic models will be developed based on machine learning algorithms
Follow-up: Myocardial infarction and mortality rates after 3+5+10 years
Prognostic value of clinical markers, CCTA, Rb PET, 15O-water PET, CT-FFR and QFR
Periodo de tiempo: Follow-up: Myocardial infarction and mortality rates after 3+5+10 years
Prognotic models will be developed based on machine learning algorithms
Follow-up: Myocardial infarction and mortality rates after 3+5+10 years
Predictive models of obstructive CAD
Periodo de tiempo: ICA: 4 weeks after inclusion
Development of pre-test probability models of obstructive CAD at ICA
ICA: 4 weeks after inclusion

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Investigador principal: Simon Winther, MD, PhD, Hospital Unit West, Herning, Denmark

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

5 de enero de 2021

Finalización primaria (Anticipado)

5 de julio de 2022

Finalización del estudio (Anticipado)

5 de enero de 2023

Fechas de registro del estudio

Enviado por primera vez

11 de enero de 2021

Primero enviado que cumplió con los criterios de control de calidad

11 de enero de 2021

Publicado por primera vez (Actual)

13 de enero de 2021

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

29 de enero de 2021

Última actualización enviada que cumplió con los criterios de control de calidad

26 de enero de 2021

Última verificación

1 de enero de 2021

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir